ShapeShapeauthorShapechevroncrossShapeShapeShapeGrouphamburgerhomeGroupmagnifyShapeShapeShaperssShape

Boehringer Ingelheim Expands Swine Team

by 5m Editor
9 February 2006, at 12:00am

US - Boehringer Ingelheim Vetmedica, Inc., (BIVI) announces the promotion of Sara Balvanz to sales representative and the addition of Abby Lauenroth as corporate account trainer for the company’s swine division.

Boehringer Ingelheim

Balvanz, who joined BIVI as corporate account trainer, is responsible for swine product sales to pork producers and veterinarians in western Iowa. Balvanz is a graduate of Iowa State University and holds a bachelor’s degree in animal science. She is based in Iowa Falls, Iowa. Lauenroth assumes the duties previously handled by Balvanz and is based in the St. Joseph, Mo, office.

“As we continue to add sales support and other resources to the swine team, we are excited to promote Sara and welcome Abby as an addition to the team,” says David Gocken, national sales manager of the BIVI swine division.

Lauenroth will work with BIVI swine product distributors across the United States in sales and product training. She received a double major in animal science and dairy science from Iowa State University in Ames, Iowa.

“Abby’s livestock background and education make her a tremendous asset to BIVI and our customers,” says Keat Catlett, manager, of the BIVI swine distribution.

Boehringer Ingelheim Vetmedica, Inc. (St. Joseph, Mo.), is a subsidiary of Boehringer Ingelheim Corporation (based in Ridgefield, Conn.), and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 144 affiliates in 45 countries and nearly 36,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2004, Boehringer Ingelheim posted net sales of U.S. $10.2 billion (8.2 billion euro) while spending nearly one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.

Source: Boehringer Ingelheim Animal Health - 9th February 2006

5m Editor